How Novartis dominates the Age Related Macular Degeneration (AMD) Market

AMD is a leading cause of blindness in the around the globe, especially in the US. It occurs when the macula, the part of the eye that helps with central vision, slowly deteriorates. The disease affects 1 in 10 people over the age of 55, and as the population ages, the number of people with AMD is only going to increase. There is no cure for AMD, but there are treatments available that can help slow down its progression. And as demand for those treatments increases, so does the cost of care.

As part of Novartis' strategy, from time to time it acquires and divests products or entire businesses, and enters into strategic alliances and collaborations. For example, it previously announced plans to divest the Sandoz US dermatology business and US oral solids portfolio, and it recently completed the spin-off of its Alcon Division, the acquisition of the assets associated with Xiidra, and the acquisition of The Medicines Company. Novartis' alliances and acquisitions are a significant source of its growth.
In addition, as part of the company's strategy, from time to time it reassesses the optimal organization of its business, such as its ongoing efforts to centralize and optimize manufacturing and business services organizations.

This report focuses on top manufacturers in global market, with revenue and market share for each manufacturer, covering
Novartis
Genentech (Roche)
Bayer AG
Regeneron Pharmaceuticals, Inc

Based on estimates done by Flair Intelligence, The market have very limited drug launches i.e. 4 drug and all are patented drug. Thus only 4-5 companies are operating in the market. Thus Novartis hold more than 90% share in the global market.

For complete Table of Contents visit @ https://flairintelligence.com/product/global-age-related-macular-degeneration-market-report-2020/

On the basis of type, this report displays the revenue, market share and growth rate of each type, primarily split into
Dry AMD
Wet AMD

By Drug Type, the market can be split into
Ranibizumab
Aflibercept
Brolucizumb
Conbercept
Other


On the basis of end user, this report displays the revenue, market share and growth rate of each type, primarily split into
Hospitals & Clinics
Ambulatory Centres
Others

For further query on report write to info@flairintelligence.com

Office A & B, Kakade Terrace
Warje, Pune 411058

About Us
Flair Intelligence is market research and consulting firm, with a vast expertise in technology and consumer goods reports. Our colossal repository of research reports, would present you with an in depth details about the market ranging from evolving trends, competitive analysis and bench marking, lucrative investment pockets, which will help your business drive profitable growth. Unlike other market research firms, we do not publish bundles of reports. On a yearly basis of we publish only 30-40 reports.
Our Major Services:
• Custom Research
• Industry Monitoring Services
• Syndicate Research

This release was published on openPR.